Moderna and Merck Cancer Vaccine Shows Promise in Melanoma Trial

In a significant development for cancer vaccines, pharmaceutical giants Moderna and Merck announced in August that their large-scale clinical trial for a melanoma treatment met its objectives. Following surgical removal of tumors, participants received a personalized vaccine that successfully reduced the recurrence and widespread dissemination of melanoma. This outcome provides the strongest evidence to date that personalized vaccines can substantially improve existing cancer treatments.

The combination of surgical removal and vaccination met the study's primary goal: significantly extending survival without melanoma recurrence, outperforming the biological drug Keytruda, a form of immunotherapy. Melanoma, though accounting for only about 1% of skin cancers, is responsible for most skin cancer deaths.

Analysts believe Moderna's valuation, around $55 billion after a 350% stock surge this year, already reflects expectations that personalized vaccines will help cure many other cancer types in the future. Moderna and Merck are now investigating the vaccine's efficacy against other cancers, including non-small cell lung cancer, pancreatic cancer, and renal cell carcinoma, the most common type of kidney cancer in adults. The treatment has also been tested in Israel as part of research studies.